• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法布里肾病的病理学和发病机制途径。

Pathology and pathogenic pathways in fabry nephropathy.

机构信息

Nephrology and Dialysis Unit, Belcolle Hospital, Via Sammartinese, snc, 01100, Viterbo, Italy.

Facultad de Ciencias Exactas, Departamento de Ciencias Biológicas, Asociado CIC PBA, Instituto de Estudios Inmunológicos y Fisiopatológicos [IIFP], UNLP, CONICET, La Plata, Argentina.

出版信息

Clin Exp Nephrol. 2021 Sep;25(9):925-934. doi: 10.1007/s10157-021-02058-z. Epub 2021 Mar 26.

DOI:10.1007/s10157-021-02058-z
PMID:33768330
Abstract

BACKGROUND

The pathophysiology of renal damage in Fabry nephropathy involves a complex biological mechanism. The intracellular deposition globotriaosylceramide (Gb3) is just the first step of the mechanism. The glycolipid deposition occurs in all renal cells (endothelial, epithelial and mesangial cells). It stimulates many biological processes, including cytokine release, epithelial-mesenchymal transdifferentiation, oxidative stress and the remodelling of vascular walls, resulting in subtle initial inflammation and eventually tissue fibrosis. It has been hypothesized that the processes activated by Gb3 deposition can subsequently progress independently of cellular deposition and that even Gb3 clearance by specific therapy cannot retard or stop these pathways.

AIM

This review aims to gather the reported evidence of these cellular alterations and the resulting histological changes. Our approach is similar to a routine study of kidney biopsy.

RESULTS

In the first part of the review, "histology" section, we describe the structures involved (glomeruli, vessels, tubules and interstitium) from a histological point of view. While in the second part, "pathogenesis" section, we present some interpretations about the implicated pathways based on the up-to-date available evidence.

摘要

背景

法布里肾病肾损伤的病理生理学涉及复杂的生物学机制。细胞内糖脂基三己糖苷(Gb3)的沉积只是该机制的第一步。糖脂沉积发生在所有的肾细胞(内皮细胞、上皮细胞和系膜细胞)中。它刺激了许多生物学过程,包括细胞因子释放、上皮-间充质转化、氧化应激和血管壁重塑,导致细微的初始炎症,最终导致组织纤维化。有人假设,Gb3 沉积激活的过程可以独立于细胞沉积而进一步发展,即使通过特定的治疗清除 Gb3 也不能延缓或阻止这些途径。

目的

本综述旨在收集关于这些细胞改变和由此产生的组织学变化的报告证据。我们的方法类似于对肾脏活检的常规研究。

结果

在综述的第一部分,即“组织学”部分,我们从组织学的角度描述了涉及的结构(肾小球、血管、肾小管和间质)。而在第二部分,即“发病机制”部分,我们根据最新的现有证据对涉及的途径提出了一些解释。

相似文献

1
Pathology and pathogenic pathways in fabry nephropathy.法布里肾病的病理学和发病机制途径。
Clin Exp Nephrol. 2021 Sep;25(9):925-934. doi: 10.1007/s10157-021-02058-z. Epub 2021 Mar 26.
2
Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease.不同肾细胞类型中的底物特异性基因表达谱与法布里病相关。
Mol Med Rep. 2015 Oct;12(4):5049-57. doi: 10.3892/mmr.2015.4010. Epub 2015 Jul 1.
3
Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide.由球三糖基鞘氨醇和球三糖基神经酰胺诱导的肾小管上皮细胞上皮-间质转化
PLoS One. 2015 Aug 20;10(8):e0136442. doi: 10.1371/journal.pone.0136442. eCollection 2015.
4
Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis.法布里肾病的发病机制:纤维化的途径。
Mol Genet Metab. 2020 Feb;129(2):132-141. doi: 10.1016/j.ymgme.2019.10.010. Epub 2019 Oct 30.
5
Bedside Stereomicroscopy of Fabry Kidney Biopsies: An Easily Available Method for Diagnosis and Assessment of Sphingolipid Deposits.法布里病肾活检的床边体视显微镜检查:一种易于获得的鞘脂沉积诊断和评估方法。
Nephron. 2018;138(1):13-21. doi: 10.1159/000479751. Epub 2017 Aug 26.
6
Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.免疫组织化学诊断法在石蜡包埋肾组织切片中对法布里肾病的诊断及糖鞘脂沉积的定位。
Virchows Arch. 2012 Feb;460(2):211-21. doi: 10.1007/s00428-011-1182-y. Epub 2011 Dec 29.
7
Contribution of inflammatory pathways to Fabry disease pathogenesis.炎症通路在法布瑞病发病机制中的作用。
Mol Genet Metab. 2017 Nov;122(3):19-27. doi: 10.1016/j.ymgme.2017.09.004. Epub 2017 Sep 13.
8
Pathogenic pathways of renal damage in Fabry nephropathy: interplay between immune cell infiltration, apoptosis and fibrosis.法布里肾病中肾脏损伤的致病途径:免疫细胞浸润、细胞凋亡和纤维化的相互作用。
J Nephrol. 2024 Apr;37(3):625-634. doi: 10.1007/s40620-024-01908-9. Epub 2024 Mar 21.
9
Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.转化生长因子-β1 和血管内皮生长因子在法布里病肾病中的可能作用。
Int J Mol Med. 2012 Dec;30(6):1275-80. doi: 10.3892/ijmm.2012.1139. Epub 2012 Sep 24.
10
Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.α-半乳糖苷酶A基因敲除小鼠(法布里病模型)中球三糖基神经酰胺异构体、球三糖基鞘氨醇及其类似物的分布
PLoS One. 2015 Dec 14;10(12):e0144958. doi: 10.1371/journal.pone.0144958. eCollection 2015.

引用本文的文献

1
Fabry Disease Beyond Storage: The Role of Inflammation in Disease Progression.法布里病:超越贮积现象——炎症在疾病进展中的作用
Int J Mol Sci. 2025 Jul 22;26(15):7054. doi: 10.3390/ijms26157054.
2
Impact of ER stress and the unfolded protein response on Fabry disease.内质网应激和未折叠蛋白反应对法布里病的影响。
EBioMedicine. 2025 May;115:105733. doi: 10.1016/j.ebiom.2025.105733. Epub 2025 Apr 28.
3
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies.法布里病:对病理生理学和新型治疗策略的见解

本文引用的文献

1
SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, 'diabetic nephropathy', IgA nephropathy and podocytopathies with FSGS lesions.SGLT2 抑制剂需要重新考虑慢性肾脏病、“糖尿病肾病”、IgA 肾病和伴有 FSGS 病变的足细胞病的基本范式。
Nephrol Dial Transplant. 2022 Aug 22;37(9):1609-1615. doi: 10.1093/ndt/gfaa329.
2
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative.法布里病疾病进展的早期指标,这些指标可能提示需要开始进行针对该疾病的治疗:基于专家意见的PREDICT-FD改良德尔菲共识倡议的结果
BMJ Open. 2020 Oct 10;10(10):e035182. doi: 10.1136/bmjopen-2019-035182.
3
Biomedicines. 2025 Mar 4;13(3):624. doi: 10.3390/biomedicines13030624.
4
The importance of a multidisciplinary approach in two tricky cases: the perfect match for Fabry disease.多学科方法在两个棘手病例中的重要性:法布里病的完美匹配
BMC Nephrol. 2025 Feb 13;26(1):77. doi: 10.1186/s12882-025-04009-2.
5
Screening for Fabry Disease-Related Mutations Among 829 Kidney Transplant Recipients.829例肾移植受者中与法布里病相关突变的筛查
J Clin Med. 2024 Nov 22;13(23):7069. doi: 10.3390/jcm13237069.
6
Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms.补体系统与黏附分子在法布瑞氏病中的交锋:对发病机制和疾病机制的深入了解。
Int J Mol Sci. 2024 Nov 14;25(22):12252. doi: 10.3390/ijms252212252.
7
Exploring the diagnostic potential of miRNA signatures in the Fabry disease serum: A comparative study of automated and manual sample isolations.探讨 miRNA 特征在法布里病血清中的诊断潜力:自动化与手动样本分离的比较研究。
PLoS One. 2024 Oct 28;19(10):e0301733. doi: 10.1371/journal.pone.0301733. eCollection 2024.
8
The role of podocyte injury in the pathogenesis of Fabry disease nephropathy.足细胞损伤在法布瑞病肾病发病机制中的作用。
J Bras Nefrol. 2024 Jul-Sep;46(3):e20240035. doi: 10.1590/2175-8239-JBN-2024-0035en.
9
Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications.法布里病中的炎症:阶段、分子途径及治疗意义
Front Cardiovasc Med. 2024 Jun 12;11:1420067. doi: 10.3389/fcvm.2024.1420067. eCollection 2024.
10
Identification of a novel nonsense mutation in α-galactosidase A that causes Fabry disease in a Chinese family.鉴定导致中国一人家族 Fabry 病的α-半乳糖苷酶 A 新型无义突变。
Ren Fail. 2024 Dec;46(2):2362391. doi: 10.1080/0886022X.2024.2362391. Epub 2024 Jun 7.
Assessment of plasma lyso-Gb for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.评估 Fabry 病患者接受米加司他治疗时的血浆溶菌酶 Gb 水平,以监测治疗反应。
Genet Med. 2021 Jan;23(1):192-201. doi: 10.1038/s41436-020-00968-z. Epub 2020 Sep 30.
4
Unraveling the mystery of Gaucher bone density pathophysiology.解析戈谢病骨密度病理生理学之谜。
Mol Genet Metab. 2021 Feb;132(2):76-85. doi: 10.1016/j.ymgme.2020.07.011. Epub 2020 Aug 1.
5
Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.法布里肾病中足细胞内神经节苷脂 GM3 的积累与足细胞进行性丢失有关。
J Am Soc Nephrol. 2020 Apr;31(4):865-875. doi: 10.1681/ASN.2019050497. Epub 2020 Mar 3.
6
Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis.阿加糖酶β治疗的女性法布里病患者的心肌病与肾功能:治疗前与治疗后分析
ESC Heart Fail. 2020 Jun;7(3):825-834. doi: 10.1002/ehf2.12647. Epub 2020 Feb 26.
7
Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.增强型血小板反应蛋白 1 导致法布雷病诱导多能干细胞来源的血管内皮细胞功能障碍。
EBioMedicine. 2020 Feb;52:102633. doi: 10.1016/j.ebiom.2020.102633. Epub 2020 Jan 23.
8
Synergistic Effects of N-Acetylcysteine and Mesenchymal Stem Cell in a Lipopolysaccharide-Induced Interstitial Cystitis Rat Model.N-乙酰半胱氨酸和间充质干细胞对脂多糖诱导的间质性膀胱炎大鼠模型的协同作用。
Cells. 2019 Dec 29;9(1):86. doi: 10.3390/cells9010086.
9
Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease.快速、蛋白质组学尿液检测法用于监测 Fabry 病中进行性器官疾病。
J Med Genet. 2020 Jan;57(1):38-47. doi: 10.1136/jmedgenet-2019-106030. Epub 2019 Sep 13.
10
Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.酶替代疗法可清除法布里病足细胞培养模型中的Gb3沉积物,但无法恢复改变的细胞信号传导。
Cell Physiol Biochem. 2019;52(5):1139-1150. doi: 10.33594/000000077.